SOLIRIS Drug Insight

“SOLIRIS Market Size, Forecast, and Drug Insight – 2032” report offers an in-depth analysis of both the market and emerging insights regarding SOLIRIS for the treatment of Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis (gMG), and Paroxysmal Nocturnal Hemoglobinuria (PNH) in the 7MM. A detailed picture of the SOLIRIS in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the SOLIRIS. The report provides insight about the mechanism of action, dosage, and administration, as well as research and development activity, including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments, including the SOLIRIS market forecast, analysis in the 7MM, descriptive analysis such as SWOT, analyst views, a comprehensive overview of market competitors, and a brief about emerging therapies.

Drug Summary

SOLIRIS (Eculizumab), the active ingredient of SOLIRIS, is a recombinant monoclonal antibody that recognizes and adheres to antigens present in the human body. It adheres to the C5 complement protein and blocks it. The C5 complement protein is a part of the immune system’s complement cascade, whose activation is responsible for developing the above conditions.

SOLIRIS (eculizumab) is Alexion Pharmaceuticals’ drug indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis (gMG), and Paroxysmal Nocturnal Hemoglobinuria (PNH) (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). The effectiveness of SOLIRIS in aHUS is based on the effects on thrombotic microangiopathy (TMA) and renal function. Prospective clinical trials in additional patients are ongoing to confirm the benefit of SOLIRIS in patients with aHUS. SOLIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the SOLIRIS description, mechanism of action, dosage and administration, research and development activities in Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis (gMG), and Paroxysmal Nocturnal Hemoglobinuria (PNH).
• Elaborated details on SOLIRIS regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SOLIRIS research and development activity in Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis (gMG), and Paroxysmal Nocturnal Hemoglobinuria (PNH) details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around SOLIRIS.
• The report contains forecasted sales of SOLIRIS for Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis (gMG), and Paroxysmal Nocturnal Hemoglobinuria (PNH) till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis (gMG), and Paroxysmal Nocturnal Hemoglobinuria (PNH).
• The report also features the SWOT analysis with analyst views for SOLIRIS in Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis (gMG), and Paroxysmal Nocturnal Hemoglobinuria (PNH).

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities' websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals, and access to available databases.

SOLIRIS Analytical Perspective by DelveInsight

• In-depth SOLIRIS Market Assessment

This report provides a detailed market assessment of SOLIRIS in Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis (gMG), and Paroxysmal Nocturnal Hemoglobinuria (PNH) in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

• SOLIRIS Clinical Assessment

The report provides the clinical trials information of SOLIRIS for Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis (gMG), and Paroxysmal Nocturnal Hemoglobinuria (PNH) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis (gMG), and Paroxysmal Nocturnal Hemoglobinuria (PNH) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SOLIRIS dominance.
• Other emerging products for Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis (gMG), and Paroxysmal Nocturnal Hemoglobinuria (PNH) are expected to give tough market competition to SOLIRIS, and the launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones and developmental activities provides the current development scenario of SOLIRIS in Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis (gMG), and Paroxysmal Nocturnal Hemoglobinuria (PNH).
• Our in-depth analysis of the forecasted sales data of SOLIRIS from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of SOLIRIS in Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis (gMG), and Paroxysmal Nocturnal Hemoglobinuria (PNH).

Key Questions

• What is SOLIRIS's product type, route of administration, and mechanism of action?
• What is the clinical trial status of the study related to SOLIRIS in Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis (gMG), and Paroxysmal Nocturnal Hemoglobinuria (PNH), and the study completion date?
• What are the key collaborations, mergers, acquisitions, licensing, and other activities related to the SOLIRIS development?
• What are the key designations that have been granted to SOLIRIS for Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis (gMG), and Paroxysmal Nocturnal Hemoglobinuria (PNH)?
• What is the forecasted market scenario of SOLIRIS for Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis (gMG), and Paroxysmal Nocturnal Hemoglobinuria (PNH)?
• What are the forecasted sales of SOLIRIS in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available in Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis (gMG), and Paroxysmal Nocturnal Hemoglobinuria (PNH), and how are they giving competition to SOLIRIS for Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis (gMG), and Paroxysmal Nocturnal Hemoglobinuria (PNH)?
• Which are the late-stage emerging therapies under development for the treatment of Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis (gMG), and Paroxysmal Nocturnal Hemoglobinuria (PNH)?